eligibility_summary
Adults (≥18) with relapsed/refractory B‑cell NHL after ≥1 systemic therapy and no standard options, measurable disease (Lugano 2014), survival ≥12 weeks, ECOG 0–1, adequate organs, CD19+ if previously CD19‑targeted, women: negative pregnancy test and contraception. Exclude prior HSCT/gene/cell therapy, CNS disease, HBV/HCV/HIV, steroids/immunosuppression, active infection, inadequate washout/recovery, active second cancer, noncompliance, pregnant/lactating.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: C752, an autologous CAR-T cell therapy (biological). Mechanism: patient T cells are engineered ex vivo to express a chimeric antigen receptor that binds CD19 on B cells, CAR engagement triggers T-cell activation (CAR/CD3ζ costimulatory signaling), expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing, independent of MHC. Targets: CD19 on malignant B cells (and normal B cells, causing B-cell aplasia) and T-cell effector pathways via CAR signaling. Indication: relapsed/refractory CD19+ B-cell NHL. Design: single-arm Phase 1 (terminated).